gene therapy

Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns
Stat
Wed, 01/3/18 - 11:09 am
Spark Therapeutics
gene therapy
Luxturna
drug pricing
rebates
Sangamo shares surge 3.4% on $12 mln ALS gene therapy collaboration with Pfizer
Marketwatch
Wed, 01/3/18 - 10:06 am
Sangamo
Pfizer
ALS
gene therapy
drug development
Trump v. Drug Makers? And 6 More Burning Biopharma Questions for 2018
Xconomy
Tue, 01/2/18 - 07:30 pm
Donald Trump
pharma industry
gene therapy
DNA testing
opioid crisis
drug development
digital healthcare
microbiome
Biopharma trends to watch in 2018
BioPharma Dive
Sat, 12/23/17 - 11:45 pm
drug pricing
M&A
gene therapy
biosimilars
opioids
ophthalmology
In gene therapy’s second big win this week, Orchard nabs $110M Series B
Endpoints
Wed, 12/20/17 - 10:44 am
gene therapy
Orchard Therapeutics
OTL-101
bubble boy syndrome
FDA rolls out an early and historic OK for Spark’s pioneering gene therapy
Endpoints
Tue, 12/19/17 - 11:06 am
FDA
Spark Therapeutics
gene therapy
Luxturna
retinal dystrophies
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
Tue, 12/12/17 - 10:50 pm
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
ASH 2017: CAR-T Wallops Blood Cancer
Motley Fool
Tue, 12/12/17 - 11:16 am
ASH2017
CAR-T
gene therapy
Novartis
Kymriah
Yescarta
Gilead Sciences
Juno Therapeutics
JCAR017
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
BioPharma Dive
Sat, 12/9/17 - 02:31 pm
ASH17
Biomarin
gene therapy
hemophilia A
valoctocogene
Gene Therapy Is Booming, But How Will We Manage The Costs?
Forbes
Sat, 12/2/17 - 11:08 am
gene therapy
drug costs
drug pricing
A Virus Shortage? BlueBird Bio Buys A Factory To Make Its Own
Forbes
Wed, 11/29/17 - 10:01 am
gene therapy
drug manufacturing
Bluebird Bio
New FDA framework points to boost for cell and gene therapies
BioPharma Dive
Tue, 11/21/17 - 09:48 am
FDA
cell therapy
gene therapy
Bayer steps up with $1.55B deal to take a lead role in commercializing Loxo’s cancer drugs
Endpoints
Tue, 11/14/17 - 07:59 am
Bayer
Loxo Oncology
cancer
gene therapy
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up
Xconomy
Wed, 11/8/17 - 09:24 am
Exonics Therapeutics
Duchenne Muscular Dystrophy
CRISPR
gene therapy
How much is your vision worth? Spark CEO Jeff Marrazzo has a price in mind
Endpoints
Wed, 11/8/17 - 09:21 am
Spark Therapeutics
Jeff Marrazzo
gene therapy
RPE65-mediated retinal dystrophy
drug pricing
Bluebird’s tweaked sickle cell gene therapy clears early test
Fierce Biotech
Wed, 11/1/17 - 06:42 pm
Bluebird Bio
sickle cell disease
gene therapy
HGB-206
With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
Endpoints
Sun, 10/29/17 - 10:04 am
Biomarin
gene therapy
BMN 270
hemophilia A
Freshly IPO’d Tocagen tweaks brain cancer gene therapy test
Fierce Biotech
Sat, 10/28/17 - 11:14 pm
Tocagen
brain cancer
gene therapy
Toca 511
Toca FC
GSK picks up NICE recommendation for Strimvelis, a €594,000 gene therapy
Fierce Pharma
Mon, 10/23/17 - 09:55 pm
GSK
NICE
UK
Strimvelis
gene therapy
ADA-SCID
We may soon have our first $1 million drug. Who will pay for it? And how?
Stat
Sat, 10/14/17 - 11:04 am
gene therapy
drug pricing
Spark Therapeutics
Luxturna

Pages